David Lau
0000-0003-0447-3094
Royal Marsden NHS Foundation Trust
1 paper found
Refreshing results…
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
Missing publications? Search for publications with a matching author name.